CODX logo

CO-DIAGNOSTICS INC

CODXNASDAQ
๐Ÿ† #5221 by market capEarnings Mar 29 ยท PostUS Equity
$0.13โ–ผ $0.03 (โˆ’21.09%)
Market closed ยท at close
๐Ÿ””
Track CODX
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 21.1%
7dโ–ผ 49.5%
14dโ–ผ 49.1%
30dโ–ผ 76.5%
ytdโ–ผ 97.5%
1yโ–ผ 98.8%
๐ŸฆMarket Cap
$1M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-28.1%
Declining
๐Ÿ“ŠGross Margin
43.5%
Healthy
๐Ÿ’ตFCF Margin
1969.6%
Strong
โš–๏ธP/S Ratio
1.9x
Cheap
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.13 โ€“ $0.14
52-Week Range
$0.17 โ€“ $13.54
Volume (shares)
5,591
Avg Volume (shares)
โ€”
Shares Outstanding
8.8M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
$622,489
Last Q Revenue
$282,881
P/E Ratio
โ€”
P/S Ratio
1.9x
EPS (TTM)
$-23.84
Dividend Yield
โ€”
CODX logo

CO-DIAGNOSTICS INC

CODX
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About CO-DIAGNOSTICS INC

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.